Skip to main content

Advertisement

SpringerLink
Log in

Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer: a meta-analysis of the literature

  • Research Article
  • Published:
Tumor Biology

Abstract

Human epidermal growth factor receptor 2 (HER2) plays an important role in the aggressiveness and progression of gastric cancer. With the publication of trial results, we conducted a meta-analysis to investigate its prognostic significance for patients with gastric cancer. PubMed, Ovid, Web of Science, and Cochrane databases were searched. Statistical analysis was carried out by STATA version 12.0 software. The Newcastle–Ottawa scale was used to assess the quality of evidence. Fifteen studies involving 5,290 patients met the inclusion criteria. The results showed that HER2 overexpression was significantly associated with patients’ overall survival (HR = 1.56, 95 % confidence interval (CI) 1.05–2.07; Z = 6.03; P = 0.000). The results also suggested that HER2 overexpression was associated with Bormann type (odds ratio (OR) = 1.76, 95 % CI 1.19–2.59; Z = 2.85; P = 0.004), tumor differentiation (OR = 3.14, 95 % CI 1.91–5.17; Z = 4.49; P = 0.000), Lauren’s classification (OR = 6.25, 95 % CI 4.29–9.10; Z = 9.54; P = 0.000), lymph node metastasis (OR = 1.43, 95 % CI 1.15–1.77; Z = 3.23; P = 0.001), venous invasion (OR = 1.69, 95 % CI 1.15–2.48; Z = 2.67; P = 0.008), and lymphovascular invasion (OR = 1.57, 95 % CI 1.21–2.04; Z = 3.4; P = 0.001). However, it had no correlation with tumor size, depth of invasion, and tumor stage. This study showed that HER2 overexpression had an unfavorable prognostic role for patients with gastric cancer. HER2-positive expression was associated with Bormann type, Lauren’s classification, tumor differentiation, lymph node status, venous invasion, and lymphovascular invasion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.

    Article  PubMed  Google Scholar 

  2. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230:1132–9.

    Article  CAS  PubMed  Google Scholar 

  3. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 1986;232:1644–6.

    Article  CAS  PubMed  Google Scholar 

  4. Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol. 2001;12 Suppl 1:S3–8.

    Article  PubMed  Google Scholar 

  5. Ménard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene. 2003;22:6570–8.

    Article  PubMed  Google Scholar 

  6. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med. 2001;344:783–92.

    Article  CAS  PubMed  Google Scholar 

  7. Schuell B, Gruenberger T, Scheithauer W, Zielinski C, Wrba F. HER 2/neu protein expression in colorectal cancer. BMC Cancer. 2006;6:123.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Hirashima N, Takahashi W, Yoshii S, Yamane T, Ooi A. Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study. Mod Pathol. 2001;14:556–662.

    Article  CAS  PubMed  Google Scholar 

  9. Eltze E, Wülfing C, Von Struensee D, Piechota H, Buerger H, Hertle L. Cox-2 and Her2/neu co-expression in invasive bladder cancer. Int J Oncol. 2005;26:1525–31.

    CAS  PubMed  Google Scholar 

  10. Beckhardt RN, Kiyokawa N, Xi L, Liu TJ, Hung MC, el-Naggar AK, et al. HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1995;121:1265–70.

    Article  CAS  PubMed  Google Scholar 

  11. McKenzie SJ, DeSombre KA, Bast BS, Hollis DR, Whitaker RS, Berchuck A, et al. Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer. 1993;71:3942–6.

    Article  CAS  PubMed  Google Scholar 

  12. Zhang XL, Yang YS, Xu DP, Qu JH, Guo MZ, Gong Y, et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg. 2009;33:2112–8.

    Article  PubMed  Google Scholar 

  13. Yu GZ, Chen Y, Wang JJ. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognosis significance. J Cancer Res Clin Oncol. 2009;135:1331–9.

    Article  CAS  PubMed  Google Scholar 

  14. Gracía I, Vizoso F, Martin A, Sanz L, Abdel-Lah O, Raigoso P, et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol. 2003;10:234–41.

    Article  Google Scholar 

  15. Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysis. Eur J Epidemiol. 2010;25:603–5.

    Article  PubMed  Google Scholar 

  16. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.

    Article  CAS  PubMed  Google Scholar 

  17. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008;61:991–6.

    Article  PubMed  Google Scholar 

  19. He C, Bian XY, Ni XZ, Shen DP, Shen YY, Liu H, et al. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. World J Gastroenterol. 2013;19:2171–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Kataoka Y, Okabe H, Yoshizawa A, Minamiguchie S, Yoshimura K, Haga H, et al. HER2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer. 2013;16:84–93.

    Article  CAS  PubMed  Google Scholar 

  21. Kim KC, Koh YW, Chang HM, Kim TH, Yook JH, Kim BS, et al. Evaluation of HER2 protein expression in gastric carcinoma: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol. 2011;18:2833–40.

    Article  PubMed  Google Scholar 

  22. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Müller W. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series. Cell Oncol. 2010;32:57–65.

    PubMed  PubMed Central  Google Scholar 

  23. Xie SD, Xu CY, Shen JG, Jiang ZN, Wang LB. HER2/neu protein expression in gastric cancer is associated with poor survival. Mol Med Rep. 2009;2:943–6.

    Article  CAS  PubMed  Google Scholar 

  24. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797–805.

    Article  CAS  PubMed  Google Scholar 

  25. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 2006;51:1371–9.

    Article  CAS  PubMed  Google Scholar 

  26. Lee KE, Lee HJ, Kim YH, Yu HJ, Yang HK, Kim WH, et al. Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Jpn J Clin Oncol. 2003;33:173–9.

    Article  PubMed  Google Scholar 

  27. Pinto-de-Sousa J, David L, Almeida R, Leitão D, Preto JR, Seixas M, et al. c-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. Int J Surg Pathol. 2002;10:247–56.

    Article  CAS  PubMed  Google Scholar 

  28. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinoma. Cancer. 1999;85:1894–902.

    Article  CAS  PubMed  Google Scholar 

  29. Kim JP, Oh ST, Hwang TS, Chi JG. The prognostic significance of c-erbB-2 and p-53 protein expression in gastric carcinoma- a multivariate analysis of prognostic factors. J Korean Med Sci. 1994;9:248–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Mizutani T, Onda M, Tokunaga A, Yamanaka N, Sugisaki Y. Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer. 1993;72:2083–8.

    Article  CAS  PubMed  Google Scholar 

  31. Uchino S, Tsuda H, Maruyama K, Kinoshita T, Sasako M, Saito T, et al. Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer. 1993;72:3179–84.

    Article  CAS  PubMed  Google Scholar 

  32. Yonemura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S, et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res. 1991;51:1034–8.

    CAS  PubMed  Google Scholar 

  33. Sakai K, Mori S, Kawamoto T, Taniguchi S, Kobori O, Morioka Y, et al. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinoma. J Natl Cancer Inst. 1986;77:1047–52.

    CAS  PubMed  Google Scholar 

  34. Roder DM. The epidemiology of gastric cancer. Gastric Cancer. 2002;5 Suppl 1:5–11.

    Article  PubMed  Google Scholar 

  35. Cooperative Study Group of HER2 in China. Multicenter study on HER-2/neu gene amplification and protein expression in patients with gastric cancer. Chin J Dig. 2006;26:657–60.

    Google Scholar 

  36. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523–9.

    Article  CAS  PubMed  Google Scholar 

  37. Yan B, Yau EX, Bte Omar SS, Ong CW, Pang B, Yeoh KG, et al. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol. 2010;63:839–42.

    Article  PubMed  Google Scholar 

  38. Kim MA, Jung EJ, Lee HS, Lee HE, Jeon YK, Yang HK, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol. 2007;38:1386–93.

    Article  CAS  PubMed  Google Scholar 

  39. Marx AH, Tharun L, Muth J, Dancau AM, Simon R, Yekebas E, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol. 2009;40:769–77.

    Article  CAS  PubMed  Google Scholar 

  40. Okegawa T, Kinjo M, Nutahara K, Higashihara E. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int J Urol. 2006;13:1197–201.

    Article  CAS  PubMed  Google Scholar 

  41. Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcome—a systematic review. Int J Cancer. 2012;130:2845–56.

    Article  CAS  PubMed  Google Scholar 

  42. Dang HZ, Yu Y, Jiao SC. Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis. World J Gastroenterol. 2012;18:2402–7.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Jørgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer—a system analysis of data from the literature. J Cancer. 2012;3:137–44.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16:273–8.

    Article  CAS  PubMed  Google Scholar 

  45. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012;23:2656–62.

    Article  CAS  PubMed  Google Scholar 

  46. Gómez-Martin C, Garralda E, Echarri MJ, Ballesteros A, Arcediano A, Rodriguez-Peralto JL, et al. HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. J Clin Pathol. 2012;65:751–7.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Sasano H, Date F, Imatani A, Asaki S, Nagura H. Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol. 1993;24:584–9.

    Article  CAS  PubMed  Google Scholar 

  48. Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene. 2000;19:6115–21.

    Article  CAS  PubMed  Google Scholar 

  49. Tokunaga A, Onda M, Okuda T, Teramoto T, Fujita I, Mizutani T, et al. Clinical significance of epidermal growth factor (EGF), EGF receptor and c-erbB-2 in human gastric cancer. Cancer. 1995;75(6 Suppl):1418–25.

    Article  CAS  PubMed  Google Scholar 

  50. Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol. 2011;18:53–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Gastric Surgery, Liaoning Cancer Hospital and Institute, 44 Xiaoheyan Road, Dadong District, Shenyang, 110042, China

    Ji-wang Liang, Jian-jun Zhang, Tao Zhang & Zhi-chao Zheng

Authors
  1. Ji-wang Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jian-jun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tao Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhi-chao Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ji-wang Liang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liang, Jw., Zhang, Jj., Zhang, T. et al. Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer: a meta-analysis of the literature. Tumor Biol. 35, 4849–4858 (2014). https://doi.org/10.1007/s13277-014-1636-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-1636-3

Keywords

Search

Navigation